Adverse Events with Biomedicines

Giuseppe Tridente is currently Professor Emeritus of Immunology at the University of Verona, where he was Dean of the Medical Faculty, founder of the Institute of Immunological Sciences, and Director of the Department of Pathology. In 1992 he founded and directed the “Green Channel” Veneto Regional Centre of Surveillance on Adverse Events to Vaccines. His research, mainly devoted to immunopathology, include experimental oncology, tumor immunology, histocompatibility and transplantation, pathophysiology of the thymus, HIV, and adverse events following immunization. He has 146 publications listed on MEDLINE and is also the author of the first Italian textbook on immunology and immunopathology (1979).

Part I General Aspects: 1 Introduction.- 2 Adverse drug events to biomedicines.- 3 Systemic syndromes caused by biomedicines.- Part II Monoclonal antibodies: 4 Monoclonal antibodies.- 5 Abciximab.- 6 Adalimumab.- 7 Alemtuzumab.- 8 Basiliximab.- 9 Belimumab.- 10 Bevacizumab.- 11 Brentuximab.- 12 Canakinumab.- 13 Catumaxomab.- 14.  Certolizumab.- 15 Cetuximab.- 16 Daclizumab.-17 Denosumab.- 18  Eculizumab.- 19 Edrecolomab.- 20 Efalizumab.- 21 Gemtuzumab.- 22 Golimumab.- 23 Ibritumomab.- 24 Infliximab.- 25 Ipilimumab.- 26 Muromonab.- 27 Natalizumab.- 28 Nimotuzumab.- 29 Ofatumumab.- 30 Omalizumab.- 31 Palivizumab.- 32 Panitumumab.- 33 Pertuzumab.- 34Ranibizumab.- 35 Rituximab.- 36 Tocilizumab.- 37 Tositumomab.- 38 Trastuzumab.- 39 Ustekinumab.- Part III Fusion proteins: 40 Fusion proteins.- 41 Abatacept.- 42 Aflibercept.- 43 Alefacept.- 44 Belatacept.- 45 Etanercept.- 46 Rilonacept.- 47 Romiplostim.- Part IV Cytokines : 48 Cytokines.- 49 Interleukins.- 50 Denileukin-diftitox.-51 Anakinra.- 52 Interferons.- 53 Hemopoietic stimulatory factors.- 54 Myelopoietic stimulatory factors.- 55 Thrombopoietic stimulatory factor.- 56 Pluripotent growth factors.- 57 Epidermal growth factors.- Part V Overview: 58 Biomedicines as adverse event inducers.- 59 Conclusions and perspectives.